As a result, siRNAs or γ-secretase inhibitors targeting NOTCH3 are currently under investigation to overcome therapy resistance and sensitize pancreatic and non-small cell lung cancer to treatment with gemcitabine (Hu et al. 2018; Yao and Qian 2010). The gene discussed is NOTCH3; the disease is non-small cell lung carcinoma.